BridgeBio Oncology Therapeutics, Inc.
BBOTDrugs in Pipeline
9
Phase 3 Programs
4
Upcoming Catalysts
3
Next Catalyst
Aug 11, 2026
6dMarket Overview
Stock performance and key metrics
3 upcoming, 1 past
BBOT Earnings Report
EPS Est: $-0.55 | FQ end 2026-06
2 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
acoramidis
Amyloidosis
Acoramidis (AG10)
Amyloid Cardiomyopathy, Transthyretin-Related
Encaleret
Autosomal Dominant Hypocalcemia (ADH)
Infigratinib 0.25 mg/kg/day
Achondroplasia
BBT-207
EGFR Mutant Advanced Non-Small Cell Lung Cancer
Infigratinib 0.016 mg/kg
Achondroplasia
AG10
Amyloid Cardiomyopathy
BBT-877
Idiopathic Pulmonary Fibrosis
Infigratinib is provided as a single dose of minitablets for oral administration
Achondroplasia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
acoramidis | Phase 3 | Amyloidosis | - | - |
Acoramidis (AG10) | Phase 3 | Amyloid Cardiomyopathy, Transthyretin-Related | - | - |
Encaleret | Phase 3 | Autosomal Dominant Hypocalcemia (ADH) | - | - |
Infigratinib 0.25 mg/kg/day | Phase 3 | Achondroplasia | - | - |
BBT-207 | Phase 2 | EGFR Mutant Advanced Non-Small Cell Lung Cancer | - | - |
Infigratinib 0.016 mg/kg | Phase 2 | Achondroplasia | - | - |
AG10 | Phase 2 | Amyloid Cardiomyopathy | - | - |
BBT-877 | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
Infigratinib is provided as a single dose of minitablets for oral administration | Phase 2 | Achondroplasia | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in BridgeBio Oncology Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 9 drug candidates in BridgeBio Oncology Therapeutics, Inc.'s (BBOT) pipeline across Phase 3, Phase 2. Its lead program is acoramidis (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is BridgeBio Oncology Therapeutics, Inc.'s next FDA catalyst?→
BridgeBio Oncology Therapeutics, Inc.'s (BBOT) next tracked catalyst is a Phase 2 expected August 1, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BBOT biotech catalysts?→
Add BBOT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BridgeBio Oncology Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.